Centrality dependence of charged particle production at large transverse momentum in Pb-Pb collisions at sNN=2.76\sqrt{s_{\rm{NN}}} = 2.76 TeV

The inclusive transverse momentum ($p_{\rm T}$) distributions of primary charged particles are measured in the pseudo-rapidity range $|\eta|<0.8$ as a function of event centrality in Pb-Pb collisions at $\sqrt{s_{\rm{NN}}}=2.76$ TeV with ALICE at the LHC. The data are presented in the $p_{\rm T}$ range $0.15<p_{\rm T}<50$ GeV/$c$ for nine centrality intervals from 70-80% to 0-5%. The Pb-Pb spectra are presented in terms of the nuclear modification factor $R_{\rm{AA}}$ using a pp reference spectrum measured at the same collision energy. We observe that the suppression of high-$p_{\rm T}$ particles strongly depends on event centrality. In central collisions (0-5%) the yield is most suppressed with $R_{\rm{AA}}\approx0.13$ at $p_{\rm T}=6$-7 GeV/$c$. Above $p_{\rm T}=7$ GeV/$c$, there is a significant rise in the nuclear modification factor, which reaches $R_{\rm{AA}} \approx0.4$ for $p_{\rm T}>30$ GeV/$c$. In peripheral collisions (70-80%), the suppression is weaker with $R_{\rm{AA}} \approx 0.7$ almost independently of $p_{\rm T}$. The measured nuclear modification factors are compared to other measurements and model calculations.Comment: 17 pages, 4 captioned figures, 2 tables, authors from page 12, published version, figures at http://aliceinfo.cern.ch/ArtSubmission/node/284

Improved upper limits on the flavor-changing neutral current decays B→Kℓ+ℓ- and B→K*(892)ℓ+ℓ-

We have searched a sample of 9.6×106 B¯B events for the flavor-changing neutral current decays B→Kℓ+ℓ- and B→K*(892)ℓ+ℓ-. We subject the latter decay to the requirement that the dilepton mass mℓℓ exceed 0.5 GeV. There is no indication of a signal. We obtain the 90% confidence level upper limits B(B→Kℓ+ℓ-) 0.5Gev0.5Gev < 1.5×10-6. The weighted-average limit is only 50% above the standard model prediction

K-Shell photodetachment of Li−: Experiment and theory

We have measured the first and second moments of the hadronic mass-squared distribution in B→Xclv, for Plepton>1.5 GeV/c. We find(MX 2−MD −2)= 0.251 ± 0.66 GeV2,((MX 2−MX 2)2)=0.576 ± 0.170 GeV4, where M¯ Dis the spin-averaged D meson mass. From that first moment and the first moment of the photon energy spectrum in b→s γ, we find the heavy quark effective theory parameter λ1(in the modified minimal subtraction renormalization scheme, to order 1/MB 3and γ0αs 2) to be −0.24±0.11GeV2. Using these first moments and the B semileptonic width, and assuming parton-hadron duality, we obtain|Vcb|=0.0404±0.0013

Hematite iron oxide nano-particles: facile synthesis and their chemi-resistive response towards hydrogen

In the present work, hematite iron oxide nano-particles are synthesized through a facile wet chemical precipitation route. The phase formation behavior and microstructure evolution of the synthesized nano-particles are studied using infrared spectroscopy in conjunction with x-ray diffraction analyses and electron microscopy. Chemi-resistive type hydrogen sensing characteristics (e.g. response %, response time, recovery time) of hematite iron oxide nano-particulate sensing element are evaluated using an automated, dynamic flow gas sensing measurement set-up. The sensing characteristics are measured by varying the operating temperature (275–350 °C) of the sensor and concentration of hydrogen (250–1660 ppm). From the operating temperature dependence of response and recovery times, we have estimated the respective activation energies for response and recovery processes

Delivery Systems for in Vivo use of Nucleic Acid Drugs

The notorious biotechnological advance of the last few decades has allowed the development of experimental methods for understanding molecular mechanisms of genes and new therapeutic approaches. Gene therapy is maturing into a viable, practical method with the potential to cure a variety of human illnesses. Some nucleic-acid-based drugs are now available for controlling the progression of genetic diseases by inhibiting gene expression or the activity of their gene products. New therapeutic strategies employ a wide range of molecular tools such as bacterial plasmids containing transgenic inserts, RNA interference and aptamers. A nucleic-acid based constitution confers a lower immunogenic potential and as result of the high stringency selection of large molecular variety, these drugs have high affinity and selectivity for their targets. However, nucleic acids have poor biostability thus requiring chemical modifications and delivery systems to maintain their activity and ease their cellular internalization. This review discusses some of the mechanisms of action and the application of therapies based on nucleic acids such as aptamers and RNA interference as well as platforms for cellular uptake and intracellular delivery of therapeutic oligonucleotides and their trade-offs

Delivery Systems for In Vivo use of Nucleic Acid Drugs

The notorious biotechnological advance of the last few decades has allowed the development of experimental methods for understanding molecular mechanisms of genes and new therapeutic approaches. Gene therapy is maturing into a viable, practical method with the potential to cure a variety of human illnesses. Some nucleic-acid-based drugs are now available for controlling the progression of genetic diseases by inhibiting gene expression or the activity of their gene products. New therapeutic strategies employ a wide range of molecular tools such as bacterial plasmids containing transgenic inserts, RNA interference aptamers. A nucleic-acid based constitution confers a lower immunogenic potential and as result of the high stringency selection of large molecular variety, these drugs have high affi nity and selectivity for their targets. However, nucleic acids have poor biostability thus requiring chemical modifications and delivery systems to maintain their activity and ease their cellular internalization. This review discusses some of the mechanisms of action and the application of therapies based on nucleic acids such as aptamers and RNA interference as well as platforms for cellular uptake and intracellular delivery of therapeutic oligonucleotides and their trade-offs